Neuralstem (CUR), a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds.
CUR's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types.
It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. CUR is also developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke.
Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
March 22, 2024
RegMed Investors’ (RMi) pre-open: Buy or fly, trade or fade?
March 21, 2024
RegMed Investors (RMi) Closing Bell: The cell and gene therapy sector faltered
March 21, 2024
RegMed Investors’ (RMi) pre-open: Not for nothing
March 20, 2024
RegMed Investors’ (RMi) pre-open: caution
March 19, 2024
RegMed Investors (RMi) Closing Bell: Short-volatility based trades or actual sentiment shaping?
March 19, 2024
RegMed Investors’ (RMi) pre-open: riding the wave
March 18, 2024
RegMed Investors (RMi) Closing Bell: a session of cell and gene therapy sector shifting share pricing
March 18, 2024
RegMedInvestors (RMi) Research Note – finance: bluebird bio (BLUE)Secures up to $175 M Debt Financing with Hercules Capital
35 companies, 1 interpreter!
Insight, foresight and recommendation
Neuralstem (CUR) -- 2018 openat at 42.03, slipped to 1.65 as February opened with a low of $1.52 and closed 2/16 at $1.63 ... a relatively flat to lowering chart. What's to watch?
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors